Jubilant Pharmova Ltd. benchmarking: Perfomance to industry peers

Financial

	Jubilant Pharmova	Alembic Pharma	Natco Pharma
Operational Metrics
Pharmaceuticals
Australia DMF fillings	14.0 .	n/a	n/a
Number of ANDA's Filed in Europe	38.0	21.0	n/a
Number of ANDA's Approved in Europe	37.0	19.0	n/a
Number of ANDA's Filed in Canada	24.0	21.0	n/a
Number of ANDA's Approved by Canada	24.0	20.0	n/a
Number of ANDA's Filed in USA	100.0 .	269.0 .	51.0 .
Number of ANDA's Approved By USFDA	62.0 .	226.0 .	41.0 .
US DMF Filings	98.0 .	141.0 .	58.0 .
Canada DMF fillings	42.0 .	n/a	n/a
Japan DMF Filings	15.0 .	n/a	n/a
R&D as a % of Total Sales	0.18 %	8.0 %	9.1 %
Financials
5 yr Average ROE	7.82 %	12.89 %	15.58 %
5yr average Equity Multiplier	1.96	1.39	1.17
5yr Average Asset Turnover Ratio	0.61	0.86	0.48
5yr Avg Net Profit Margin	6.45 %	11.15 %	26.79 %
Price to Book	2.58	3.33	1.96
P/E	35.65	27.95	11.04
5yr Avg Cash Conversion Cycle	-39.98 Days	9.46 Days	4.27 Days
Inventory Days	74.06 Days	99.1 Days	91.91 Days
Days Receivable	45.59 Days	66.32 Days	93.3 Days
Days Payable	149.89 Days	164.9 Days	134.54 Days
5yr Average Interest Coverage Ratio	3.78	30.59	60.49
5yr Avg ROCE	8.15 %	15.26 %	19.09 %
5yr Avg Operating Profit Margin	16.76 %	17.29 %	34.0 %
5 yr average Debt to Equity	0.55	0.14	0.06
5yr CAGR Net Profit	0.08 %	-12.64 %	33.73 %
5yr Average Return on Assets	4.12 %	9.32 %	13.46 %
Shareholdings
Promoter Holding	47.68 %	69.74 %	49.48 %
Share Pledged by Promoters	5.4 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.0 %	0.13 %	0.68 %
Change in Mutual Fund Holding (3 Yrs)	6.74 %	3.19 %	-5.43 %

Business

	Jubilant Pharmova	Alembic Pharma	Natco Pharma
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 46.89 Contract Manufacturing 17.66 Anti-allergic 9.75 Solid dosage formulations 8.71 Active Pharmaceutical Ingredient (API) 7.91 Contract Research and Development Services 7.87 India branded pharmaceuticals 0.7 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Formulations 0 API 0 Crop Health 0 API(Domestic & Exports) 0 Formulation 0 Others 0.51	Product Wise Break-Up Crop Health 0 Contract Manufacturing 0 Specialty intermediates 0 Nutritional products 0 Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0 API(Domestic & Exports) 0 Formulation 0 0 Anti-allergic 0 Formulations 83.56 Solid dosage formulations 0 India branded pharmaceuticals 0 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 16.44	Product Wise Break-Up Crop Protection 3.6 Contract Manufacturing 0 Specialty intermediates 0 Nutritional products 0 Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0 Active Pharmaceutical Ingredient (API) 3.7 Formulations 85.6 0 Anti-allergic 0 Formulations 0 Solid dosage formulations 0 India branded pharmaceuticals 0 Life science chemicals 0 API 0 Others 7.1
Segment Break-Up	Segment Break-Up Radiopharma 45.01 CDMO Sterile Injectables 20.34 Drug discovery and development solutions 16.13 Allergy Immunotherapy 9.92 Generics 8.6 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0	-	Segment Break-Up Allergy Immunotherapy 0 Pharmaceuticals 96.15 Agrochemicals 3.85 0 Life Science Ingredients 0 Radiopharma 0 Generics 0 CDMO Sterile Injectables 0 Proprietary Novel Drugs 0
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 91.35 Rest of the World 5.89 India 2.76 China 0 USA 0	Location Wise Break-Up Americas and Europe 0 Rest of the World 60.76 India 39.24 China 0 USA 0	Location Wise Break-Up Americas and Europe 0 Rest of the World 16.18 India 12.44 China 0 USA 71.37 Others 0.01
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 42.87 Allergy Immunotherapy 26.65 CDMO Sterile Injectables 18.74 Contract Research and Development 11.74 Generics 0 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0	-	Operating Profit Break-Up Allergy Immunotherapy 0 Pharmaceuticals 100.0 Agrochemicals 0 Life Science Ingredients 0 Radiopharma 0 Generics 0 CDMO Sterile Injectables 0 Proprietary Novel Drugs 0 Contract Research and Development 0
Capex	Capex CDMO 75.99 Radiopharma 15.19 Contract Research and Development 5.98 Proprietary Novel Drugs 1.46 Generics 0.65 Allergy Immunotherapy 0.63 Life Science Ingredients 0 Others 0.1	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 13.26 Proprietary Novel Drugs 2.13 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0 Others 84.61	-	Asset Break-Up Pharmaceuticals 94.5 Agrochemicals 5.5 Life Science Ingredients 0 Proprietary Novel Drugs 0 Contract Research and Development 0

Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd.

Financial

Business

SIGN UP FOR FREE